Multicenter Real-World Assessment of the Effectiveness of V-Go Wearable Insulin Delivery Device in Adult Patients with Type 2 Diabetes (ENABLE Study): A Retrospective Analysis

References

• Centers for Disease Control and Prevention. National diabetes statistics report, 2017: estimates of diabetes and its burden in the United States. Atlanta, GA: US Department of Health and Human Services; 2017. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed September 7, 2020.
   Google Scholar
• Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468–475. doi:10.2337/dc16-0985
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Association of clinical endocrinologists (AACE); American college of endocrinology (ACE). Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract. 2017;23(2):207–238.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2020. Chapter 9: pharmacologic approaches to glycemic treatment. Diabetes Care. 2020;43(Supplement 1):S98–S110. doi:10.2337/dc20-S009
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger P-M. Factors associated with injection omission/non-adherence in the global attitudes of patients and physicians in insulin therapy study. Diabetes Obes Metab. 2012;14(12):1081–1087. doi:10.1111/j.1463-1326.2012.01636.x
   PubMed Web of Science ®Google Scholar
• Leahy JL. Insulin therapy in type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2012;41(1):119–144. doi:10.1016/j.ecl.2012.03.004
   PubMed Web of Science ®Google Scholar
• Lajara R, Nikkel C, Abbott S. The clinical and economic impact of the V-Go disposable insulin delivery device for insulin delivery in patients with poorly controlled diabetes at high risk. Drugs Real World Outcomes. 2016;3(2):191–199. doi:10.1007/s40801-016-0075-4
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2019. Chapter 7: diabetes technologies. Diabetes Care. 2019;41(Supplement 1):S71–80. doi:10.2337/dc19-S007
   Web of Science ®Google Scholar
• Klonoff DC, Gutierrez A, Fleming A, Kerr D. Real-world evidence should be used in regulatory decisions about new pharmaceutical and medical device products for diabetes. J Diabetes Sci Technol. 2019;1932296819839996. doi:10.1177/1932296819839996.
   Google Scholar
• Valeritas. V-Go: instructions for patient use; 2018. Available from: https://44yunigub221yppu525xpeh2-wpengine.netdna-ssl.com/wp-content/uploads/2018/06/ART-037_Rev-J_V-GoUpdatedIFU_05252018_FNL_LowRes.pdf. Accessed September 7, 2020.
   Google Scholar
• Lajara R, Fetchick DA, Morris TL, Nikkel C. Use of V-Go® insulin delivery device in patients with sub-optimally controlled diabetes mellitus: a retrospective analysis from a large specialized diabetes system. Diabetes Ther. 2015;6(4):531–545. doi:10.1007/s13300-015-0138-7
   PubMed Web of Science ®Google Scholar
• Lajara R, Davidson JA, Nikkel CC, Morris TL. Clinical and cost-effectiveness of insulin delivery with V-Go disposable insulin delivery device versus multiple daily injections in patients with type 2 diabetes inadequately controlled on basal insulin. Endocr Pract. 2016;22(6):726–735. doi:10.4158/EP151182.OR
   Web of Science ®Google Scholar
• Lajara R, Nikkel C. Practical Considerations for switching to V-Go for insulin delivery in patients with type 2 diabetes. Pract Diabetol. 2016;5:10–15.
   Google Scholar
• Rosenfeld CR, Bohannon NJ, Bode B, et al. The V-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control. Endocr Pract. 2012;18(5):660–667. doi:10.4158/EP11362.OR
   Web of Science ®Google Scholar
• Johns BR, Jones TC, Sink JH, Cooke CE. Real-world assessment of glycemic control after V-Go® initiation in an endocrine practice in the southeastern United States. J Diabetes Sci Technol. 2014;8(5):1060–1061. doi:10.1177/1932296814537041
   Google Scholar
• Sutton D, Higdon CD, Nikkel C, Hilsinger KA. Clinical benefits over time associated with use of V-Go wearable insulin delivery device in adult patients with diabetes: a retrospective analysis. Adv Ther. 2018;35(5):631–643. doi:10.1007/s12325-018-0703-3
   PubMed Web of Science ®Google Scholar
• Everitt B, Harrison HC Jr, Nikkel C, Laswell E, Chen AMH. Clinical and economic considerations based on persistency with a novel insulin delivery device versus conventional insulin delivery in patients with type 2 diabetes: a retrospective analysis. Res Social Adm Pharm. 2019;15(9):1126–1132. doi:10.1016/j.sapharm.2018.09.016
   Web of Science ®Google Scholar
• Winter A, Lintner M, Knezevich E. V-Go insulin delivery system versus multiple daily insulin injections for patients with uncontrolled type 2 diabetes mellitus. J Diabetes Sci Technol. 2015;9(5):1111–1116. doi:10.1177/1932296815580361
   Google Scholar
• Cziraky MJ, Abbott S, Nguyen M, et al. A pragmatic clinical trial to compare the real-world effectiveness of V-Go versus standard delivery of insulin in patients with advanced type 2 diabetes. JHEOR. 2019;6(2):70–83. doi:10.36469/9731
   Google Scholar
• American Diabetes Association Standards of Medical Care in Diabetes—2020. Chapter 6: glycemic targets. Diabetes Care. 2020;43(Supplement 1):S66–S76.
   Google Scholar
• Ginsberg BH. Patch pumps for insulin. J Diabetes Sci Technol. 2019;13(1):27–33. doi:10.1177/1932296818786513
   PubMedGoogle Scholar
• Iglay K, Hannachi H, Howie PJ, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243–1252. doi:10.1185/03007995.2016.1168291
   PubMed Web of Science ®Google Scholar
• Zoungas S, Woodward M, Li Q, et al., ADVANCE Collaborative group. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57(12):2465–2474. doi:10.1007/s00125-014-3369-7
   PubMed Web of Science ®Google Scholar